DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Therapeutics' stock has fluctuated between $3.47 and $10.42 over the past 52 weeks, with a share price of $6.52 as of May 7, 2026. The company reported full-year 2025 and first-quarter 2026 financial results, with the latter showing a net loss of $10.0 million due to increased R&D expenses. Enrollment delays in the ReMEDy2 trial have pushed the interim analysis to Q4 2026. Analyst ratings are mixed, with some downgrades and others maintaining a "Moderate Buy" rating with a target price of $12.33. As of March 31, 2026, the company held $51.3 million in cash and short-term investments, expected to fund operations through 2027.

There is no strong indication of significant demand seasonality for DiaMedica Therapeutics, Inc.'s products and services. The Tickeron Seasonality Score of 50 suggests that the company is "fair valued in the industry". Demand is likely driven by clinical trial progress, regulatory approvals, and disease prevalence rather than seasonal factors.

DiaMedica Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for ischemic and vascular diseases, including preeclampsia, fetal growth restriction, and acute ischemic stroke. Their lead product candidate, DM199, aims to enhance blood flow and vascular health. Another product candidate is DM300, a potential therapy for severe acute pancreatitis.

DiaMedica Therapeutics, Inc. is incorporated in British Columbia, Canada, with operational headquarters in Minneapolis, Minnesota, United States.

DiaMedica Therapeutics' brand reputation is mixed, with positive interim results from Phase 2 clinical trials for DM199 in preeclampsia, leading to some analysts revising share price targets upward. However, there have been downgrades from Wall Street Zen and Weiss Ratings, potentially influenced by slower-than-expected enrollment in the ReMEDy2 trial and increased cash burn. Reported net losses and safety concerns about DM199 could also impact reputation.

DiaMedica Therapeutics Inc. is owned by a mix of institutional, insider, and retail investors. There are 96 institutional owners and shareholders holding a total of 11,278,408 shares. Major institutional owners include Cooperman Leon G, BlackRock, Inc., and Paragon Associates & Paragon Associates Ii Joint Venture. Significant individual insider owners include Jan Stahlberg, Koch Thomas Von, and Richard Jacinto Ii.